Neovacs Share Consolidation: Key Information

Neovacs, a company listed on Euronext Growth, announces a reverse stock split. This transaction, based on 1 new share for every 1,000 existing shares, aims to optimize its capital management. The reverse stock split, approved by the Board of Directors on May 6, 2025, will begin on June 18 and end on July 21, 2025.

This reverse stock split involves 208,080,085 shares, bringing their total number to 208,080. Shareholders will not need to take any action if they hold multiples of 1,000 shares. The excess shares will be sold on the market. Furthermore, the exercise of securities giving access to the capital will be suspended from June 16 to July 23, 2025. Transactions will be carried out via Euronext Paris.